Wednesday, October 14, 2026
ExploreSearch
Finance Via News
Via News Knowledge File

Oracle Corporation

organization80% conf.·synced Oct 14, 2026

Technology company that adopted Custom AI Companion for global workforce AI assistants

60
sourced metrics
779
relationships
20
stated objectives
8
Via News reports

Every fact below is drawn from Via News's knowledge graph and linked to the source document it came from. Nothing here is unsourced. How we source →

Key metrics · each point sourced

Price 52 Week High
313.00USD
Oct 13, 2026reference only
Stock Price
143.20USD
Oct 13, 2026reference only
Price 52 Week Low
114.99USD
Oct 13, 2026reference only
Market Cap
412483447200USD
Oct 13, 2026reference only
Stock Return Ytd
-26.8%
Oct 13, 2026reference only
Shares Outstanding
2880471000.0shares
Jun 12, 2026reference only
Cash
31289000000.0USD
May 31, 2026reference only
Total Assets
261759000000.0USD
May 31, 2026reference only
Revenue
67357000000.0USD
May 31, 2026reference only
Operating Cash Flow
31977000000.0USD
May 31, 2026reference only
Capex
55663000000.0USD
May 31, 2026reference only
Stockholders Equity
42508000000.0USD
May 31, 2026reference only
Net Income
17087000000.0USD
May 31, 2026reference only
Eps
5.83USD_per_share
May 31, 2026reference only
Rd Expense
10272000000.0USD
May 31, 2026reference only
Operating Income
20606000000.0USD
May 31, 2026reference only

Stated objectives

Oracle plans to raise up to $50 billion for cloud buildout

source
target: 50 billion USD by 2026-12-31 00:00:00stated

Raise capex forecast to around $50 billion for AI data centers

source
target: 50 billion USD stated

Oracle Cloud Infrastructure revenue growth

source
target: 4.1 billion USD (68% climb) stated

Build AI data centers

source
target: 50 billion USD capex stated

Oracle launched AI-driven supply chain tools to predict disruptions and optimize inventory levels

source
by 2025-01-01 00:00:00stated

Oracle targets continued cloud acceleration and data center capacity expansion in FY2026

source
stated

Capital spending on AI infrastructure

source
target: 500+ billion USD by 2026-01-01 00:00:00stated

Accelerate revenue and profit growth through AI infrastructure capital expenditure

source
stated

Spend on CapEx right before it starts generating revenue

source
stated

Increased guidance for 2027 revenues by $4 billion

source
target: 4 billion USD increase by 2027-01-01 00:00:00stated

Relationship graph · 779 connections

Competes with
136
Developed by
107
Covered by
97
Customer of
75
Supplies to
68
Employs
38
located in
27
headquartered in
23
partnership cancelled
OpenAI →
Partnered with
OpenAI →

Via News coverage

Pershing Square Builds Microsoft Stake as Oracle Borrows to Fund AI Data Centers
May 17, 2026
CFO AI Budgets Set to Surge 50%+ as Numero AI, BlackLine, and Oracle Race to Automate Corporate Finance
May 17, 2026
BlackLine, Oracle, and Numero AI Deploy Autonomous Agents as CFOs Plan 50%-Plus AI Budget Increases
May 15, 2026
BlackLine Launches Agentic Finance Platform as Oracle Deploys AI Across Fusion Cloud
May 13, 2026
Dell, SAP, Oracle Race to Own Enterprise AI Control Layer as Model Commoditization Accelerates
April 28, 2026
BlackLine and Oracle Race to Embed Autonomous AI Agents in Enterprise Finance
April 27, 2026
Dell, NVIDIA, Oracle Fight to Own Enterprise AI Stack as Domain Expertise Displaces Model Access
April 27, 2026
BlackLine, Oracle, and OneStream Converge on Agentic AI as CFO Autonomy Becomes the 2026 Battleground
April 26, 2026
This Knowledge File is assembled from Via News's source-traceable knowledge graph. Metrics, objectives and relationships are extracted from primary and credible secondary documents and refreshed on a schedule. Read our methodology →
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com